This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol Myers Squibb (BMY) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $72.62, marking a -0.55% move from the previous day.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $73.02, marking a +0.21% move from the previous day.
MorphoSys (MOR) Gains on Oncology Collaboration With Pfizer
by Zacks Equity Research
MorphoSys (MOR) and Pfizer collaborate to develop a combination of MOR's Monjuvi and Pfizer's checkpoint inhibitor candidate, TTI-622, for treating r/r DLBCL.
Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Bristol Myers Squibb (BMY) Stock Moves -0.26%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $75.98, moving -0.26% from the previous trading session.
Roche (RHHBY) Gets EU Nod for Lunsumio, Tecentriq Label Expansion
by Zacks Equity Research
Roche (RHHBY) obtains EU approval for Lunsumio for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) and label expansion of Tecentriq.
The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics
by Zacks Equity Research
Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.
Bristol Myers Squibb (BMY) Stock Moves -0.54%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $76.18 in the latest trading session, marking a -0.54% move from the prior day.
Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More
by Zacks Equity Research
Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Why Is Amicus Therapeutics (FOLD) Up 25.1% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.
BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
by Zacks Equity Research
Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.
Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down
by Zacks Equity Research
Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $75.07, marking a +0.15% move from the previous day.
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC
by Zacks Equity Research
Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.
Iovance (IOVA) Down After Announcing Data From Melanoma Study
by Zacks Equity Research
Results from a cohort of the phase II study evaluating Iovance's (IOVA) melanoma candidate were not as superior as data from another cohort of the same study.
Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study
by Zacks Equity Research
Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.
Exelixis (EXEL) Announces Results From Phase II HNSCC Study
by Zacks Equity Research
Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.
J&J (JNJ) Carvykti Gets EU Nod for Advanced Multiple Myeloma
by Zacks Equity Research
The European Commission approved J&J's (JNJ) BCMA-directed CAR-T cell therapy, Carvykti to treat patients with multiple myeloma who have already received multiple treatments.
The Zacks Analyst Blog Highlights Tesla, Procter & Gamble, Bristol-Myers Squibb, Wells Fargo and Intuit
by Zacks Equity Research
Tesla, Procter & Gamble, Bristol-Myers Squibb, Wells Fargo and Intuit have been included in this Analyst Blog.
Top Stock Reports for Tesla, Procter & Gamble & Bristol-Myers Squibb
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), The Procter & Gamble Company (PG), and Bristol-Myers Squibb Company (BMY).
Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Pfizer (PFE) Reports More Positive Data From Etrasimod Study
by Zacks Equity Research
Pfizer (PFE) states that data from the ELEVATE 12 and ELEVATE 52 studies will form the basis of the regulatory submissions on etrasimod expected later this year